Halobetasol + Tazarotene topical

Indications

Halobetasol + Tazarotene topical is used for: Plaque Psoriasis

Adult Dose

Plaque Psoriasis Indicated for topical treatment of plaque psoriasis in adults Apply a thin layer of lotion to affected areas qDay

Child Dose

Renal Dose

Administration

Apply thin layer to affected areas and rub gently Do not use with occlusive dressings unless directed by a physician Avoid application on the face, groin, or in the axillae

Contra Indications

Pregnancy

Precautions

Avoid use on eczematous skin; may cause severe irritation Posterior subcapsular cataracts and glaucoma reported postmarketing with topical corticosteroid use Use appropriate antimicrobial agent if skin infection is present or develops; if favorable response does not occur promptly, discontinue until infection adequately treated Photosensitivity and risk for sunburn Heightens sunburn susceptibility; avoid exposure to sunlight (eg, sunlamps); if medically necessary, minimize exposure during treatment; instruct patients to use sunscreens and protective clothing Avoid use in patients with sunburn until fully recovered; exercise caution in patients with considerable sun exposure or with inherent sensitivity to sunlight Caution if coadministered with drugs known to be photosensitizers (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides)

Pregnancy-Lactation

Pregnancy Contraindicated in women who are pregnant Based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, fetal harm may occur when administered to a pregnant female Safety in pregnant females has not been established Consider potential risks to the fetus outweighs the potential benefit to the mother from topical lotion during pregnancy; discontinue lotion as soon as pregnancy is recognized Observational studies suggest an increased risk of low birthweight in infants with the maternal use of potent or very potent topical corticosteroids Pregnancy testing Obtain a negative result for pregnancy within 2 weeks prior to therapy, which should begin during menstruation Contraception Advise females of reproductive potential to use effective contraception during treatment Tazarotene Teratogenic; unknown what level of exposure is required for teratogenicity in humans Elicits teratogenic and developmental effects associated with retinoids after topical or systemic administration in rats and rabbits Lactation No data available on the presence of tazarotene, halobetasol propionate, or its metabolites in human milk, effects on the breastfed infant, or effects on milk production after treatment After single topical doses of a 14C-tazarotene gel formulation to the skin of lactating rats, radioactivity was detected in rat milk Unknown whether topical corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk Advise breastfeeding women not to apply directly to nipple and areola to avoid direct infant exposure Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Interactions

Side Effects

Side effects of Halobetasol + Tazarotene topical : 1-10% Contact dermatitis (7%) Application site pain (3%) Folliculitis (2%) Skin atrophy (2%) Excoriation (2%) Rash (1%) Skin abrasion (1%) Skin exfoliation (1%)

Mode of Action

Precise mechanism of action in plaque psoriasis is unknown Halobetasol: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation Tazarotene: A retinoid prodrug converts to its active form, tazarotenic acid, the carboxylic acid of tazarotene, by deesterification; tazarotenic acid binds to members of the retinoic acid receptor family